Teva Provides Update On Glatiramer Acetate 40mg For Amyotrophic Lateral Sclerosis (ALS)

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced final results from the global phase II GoALS trial. The study was designed to assess the safety, tolerability and efficacy of glatiramer acetate (GA) 40 mg, given once daily as a subcutaneous injection, in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis (ALS) patients.

More: continued here

Filed under: Muscular Dystrophy on April 2nd, 2008